CCL18 and systemic sclerosis: In their retrospective cohort analysis, serum CCL-18 level was decreased in SSc patients having an improvement of pulmonary fibrosis (as measured by HRCT, PFT, and BAL analysis) and comparable to the decrease of KL-6 and SP-D [97].